Kura Oncology is a clinical-stage biopharmaceutical company whose mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives. We are advancing a number of precision medicines for the treatment of solid tumors and hematologic malignancies including ziftomenib (KO-539), a menin inhibitor, which is being studied in genetically defined subsets of patients that includes NPM1 mutant and KMT2A-rearranged acute myeloid leukemia.
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.